- Ramanan, Vijay K;
- Risacher, Shannon L;
- Nho, Kwangsik;
- Kim, Sungeun;
- Shen, Li;
- McDonald, Brenna C;
- Yoder, Karmen K;
- Hutchins, Gary D;
- West, John D;
- Tallman, Eileen F;
- Gao, Sujuan;
- Foroud, Tatiana M;
- Farlow, Martin R;
- De Jager, Philip L;
- Bennett, David A;
- Aisen, Paul S;
- Petersen, Ronald C;
- Jack, Clifford R;
- Toga, Arthur W;
- Green, Robert C;
- Jagust, William J;
- Weiner, Michael W;
- Saykin, Andrew J;
- Initiative, for the Alzheimer’s Disease Neuroimaging
Brain amyloid deposition is thought to be a seminal event in Alzheimer's disease. To identify genes influencing Alzheimer's disease pathogenesis, we performed a genome-wide association study of longitudinal change in brain amyloid burden measured by (18)F-florbetapir PET. A novel association with higher rates of amyloid accumulation independent from APOE (apolipoprotein E) ε4 status was identified in IL1RAP (interleukin-1 receptor accessory protein; rs12053868-G; P = 1.38 × 10(-9)) and was validated by deep sequencing. IL1RAP rs12053868-G carriers were more likely to progress from mild cognitive impairment to Alzheimer's disease and exhibited greater longitudinal temporal cortex atrophy on MRI. In independent cohorts rs12053868-G was associated with accelerated cognitive decline and lower cortical (11)C-PBR28 PET signal, a marker of microglial activation. These results suggest a crucial role of activated microglia in limiting amyloid accumulation and nominate the IL-1/IL1RAP pathway as a potential target for modulating this process.